Wells Fargo’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-207,270
| Closed | -$871K | – | 7824 |
|
|
2023
Q1 | $871K | Buy |
+207,270
| New | +$1.08M | ﹤0.01% | 3473 |
|
|
2022
Q4 | – | Sell |
-7,426
| Closed | -$43K | – | 7957 |
|
|
2022
Q3 | $43K | Buy |
7,426
+1,575
| +27% | +$9.81K | ﹤0.01% | 5026 |
|
|
2022
Q2 | $35K | Buy |
5,851
+5,351
| +1,070% | +$27.4K | ﹤0.01% | 5196 |
|
|
2022
Q1 | $2K | Sell |
500
-17
| -3% | -$51 | ﹤0.01% | 6737 |
|
|
2021
Q4 | $1K | Buy |
517
+1
| +0.2% | +$2 | ﹤0.01% | 7151 |
|
|
2021
Q3 | $2K | Sell |
516
-27
| -5% | -$74 | ﹤0.01% | 6636 |
|
|
2021
Q2 | $1K | Buy |
543
+166
| +44% | +$398 | ﹤0.01% | 6829 |
|
|
2021
Q1 | $1K | Sell |
377
-48,533
| -99% | -$158K | ﹤0.01% | 6835 |
|
|
2020
Q4 | $157K | Buy |
48,910
+48,562
| +13,955% | +$162K | ﹤0.01% | 5184 |
|
|
2020
Q3 | $1K | Sell |
348
-260
| -43% | -$332 | ﹤0.01% | 6272 |
|
|
2020
Q2 | $1K | Buy |
608
+158
| +35% | +$167 | ﹤0.01% | 6229 |
|
|
2020
Q1 | $0 | Buy |
+450
| New | +$516 | ﹤0.01% | 7322 |
|
|
2019
Q3 | – | Sell |
-2,425
| Closed | -$2K | – | 7032 |
|
|
2019
Q2 | $2K | Sell |
2,425
-140,674
| -98% | -$130K | ﹤0.01% | 6218 |
|
|
2019
Q1 | $138K | Sell |
143,099
-14,070
| -9% | -$14.8K | ﹤0.01% | 5006 |
|
|
2018
Q4 | $115K | Buy |
157,169
+102,605
| +188% | +$169K | ﹤0.01% | 5221 |
|
|
2018
Q3 | $118K | Buy |
54,564
+1,335
| +3% | +$3.31K | ﹤0.01% | 5283 |
|
|
2018
Q2 | $265K | Buy |
53,229
+24,966
| +88% | +$109K | ﹤0.01% | 4879 |
|
|
2018
Q1 | $111K | Buy |
28,263
+231
| +0.8% | +$812 | ﹤0.01% | 5262 |
|
|
2017
Q4 | $75K | Buy |
+28,032
| New | +$82.2K | ﹤0.01% | 5419 |
|
|
2017
Q3 | – | Sell |
-23
| Closed | – | – | 6708 |
|
|
2017
Q2 | $0 | Sell |
23
-2
| -8% | -$8 | ﹤0.01% | 6735 |
|
|
2017
Q1 | $0 | Hold |
25
| – | – | ﹤0.01% | 6766 |
|
|
2016
Q4 | $0 | Buy |
25
+2
| +9% | +$8 | ﹤0.01% | 6706 |
|
|
2016
Q3 | $0 | Hold |
23
| – | – | ﹤0.01% | 6615 |
|
|
2016
Q2 | $0 | Sell |
23
-6,847
| -100% | -$31.4K | ﹤0.01% | 6693 |
|
|
2016
Q1 | $37K | Sell |
6,870
-957
| -12% | -$7.65K | ﹤0.01% | 5335 |
|
|
2015
Q4 | $96K | Sell |
7,827
-19
| -0.2% | -$254 | ﹤0.01% | 4937 |
|
|
2015
Q3 | $115K | Sell |
7,846
-1,102
| -12% | -$19K | ﹤0.01% | 4790 |
|
|
2015
Q2 | $175K | Buy |
8,948
+5,160
| +136% | +$99.6K | ﹤0.01% | 4685 |
|
|
2015
Q1 | $68K | Buy |
3,788
+3,166
| +509% | +$71.3K | ﹤0.01% | 4903 |
|
|
2014
Q4 | $15K | Buy |
622
+5
| +0.8% | +$116 | ﹤0.01% | 5490 |
|
|
2014
Q3 | $15K | Sell |
617
-337
| -35% | -$8.76K | ﹤0.01% | 5444 |
|
|
2014
Q2 | $27K | Buy |
954
+754
| +377% | +$22.7K | ﹤0.01% | 5246 |
|
|
2014
Q1 | $7K | Buy |
+200
| New | +$6.83K | ﹤0.01% | 5493 |
|
Other funds holding CTIC
Wells Fargo's CTIC Position: Q2 2023 in Review
Wells Fargo sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 207,270 shares — an estimated $871K sold.
Wells Fargo first reported a position in CTIC in Q1 2014 and held it in 33 quarters. The position peaked at $871K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Wells Fargo reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 207,270 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $871K.
- Wells Fargo first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 33 quarters.
- Wells Fargo's CTI BioPharma Corp. (DE) Common Stock position peaked at $871K in Q1 2023.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.